IL148469A0 - Apoptin-associating protein - Google Patents

Apoptin-associating protein

Info

Publication number
IL148469A0
IL148469A0 IL14846900A IL14846900A IL148469A0 IL 148469 A0 IL148469 A0 IL 148469A0 IL 14846900 A IL14846900 A IL 14846900A IL 14846900 A IL14846900 A IL 14846900A IL 148469 A0 IL148469 A0 IL 148469A0
Authority
IL
Israel
Prior art keywords
apoptin
associating protein
novel therapeutic
novel
apoptosis
Prior art date
Application number
IL14846900A
Other languages
English (en)
Original Assignee
Leadd Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99202858A external-priority patent/EP1081226A1/en
Priority claimed from EP99203465A external-priority patent/EP1108785A1/en
Application filed by Leadd Bv filed Critical Leadd Bv
Publication of IL148469A0 publication Critical patent/IL148469A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL14846900A 1999-09-02 2000-09-01 Apoptin-associating protein IL148469A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99202858A EP1081226A1 (en) 1999-09-02 1999-09-02 Apoptin-associating protein
EP99203465A EP1108785A1 (en) 1999-10-21 1999-10-21 Apoptin-associating protein
PCT/NL2000/000612 WO2001016165A2 (en) 1999-09-02 2000-09-01 Apoptin-associating protein

Publications (1)

Publication Number Publication Date
IL148469A0 true IL148469A0 (en) 2002-09-12

Family

ID=26153361

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14846900A IL148469A0 (en) 1999-09-02 2000-09-01 Apoptin-associating protein
IL148469A IL148469A (en) 1999-09-02 2002-03-03 Apoptin-associating protein, a method for its production and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL148469A IL148469A (en) 1999-09-02 2002-03-03 Apoptin-associating protein, a method for its production and use thereof

Country Status (20)

Country Link
US (2) US7317096B1 (pl)
EP (1) EP1083224B1 (pl)
JP (1) JP2003510030A (pl)
CN (1) CN100513565C (pl)
AT (1) ATE347597T1 (pl)
AU (1) AU781127B2 (pl)
BR (1) BR0013743A (pl)
CA (1) CA2383784A1 (pl)
CY (1) CY1106355T1 (pl)
DE (1) DE60032201T2 (pl)
DK (1) DK1083224T3 (pl)
EA (1) EA005933B1 (pl)
ES (1) ES2277815T3 (pl)
HU (1) HUP0202688A2 (pl)
IL (2) IL148469A0 (pl)
NO (1) NO20021067L (pl)
NZ (1) NZ517740A (pl)
PL (1) PL204275B1 (pl)
PT (1) PT1083224E (pl)
WO (1) WO2001016165A2 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2393859A1 (en) * 1999-12-10 2001-06-14 Leadd B.V. Apoptin-associating protein
MX2010011145A (es) 2008-04-11 2011-04-11 Merrimack Pharmaceuticals Inc Enlazadores de la albumina de suero humana y conjugados de la misma.
WO2011100428A2 (en) * 2010-02-10 2011-08-18 The Uab Research Foundation Compositions for improving bone mass

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9002008A (nl) * 1990-09-12 1992-04-01 Stichting Centr Diergeneeskund Recombinant dna en rna en daarvan afgeleide produkten.
EP0878546A1 (en) * 1997-04-15 1998-11-18 Leadd B.V. A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or apoptin
AU4388296A (en) 1994-12-22 1996-07-10 Novartis Ag Nuclear protein serine/threonine kinases
EP0830604B1 (en) * 1995-06-07 2003-05-28 Leadd B.V. Uses of apoptin
WO1998039448A2 (en) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 human secreted proteins
NZ502800A (en) * 1997-08-12 2002-10-25 Leadd B The use of apoptin in determining the transforming capability of tumorigenic or tumor promoting agents
EP0927757A1 (en) * 1997-12-03 1999-07-07 Leadd B.V. Methods and means for inducing apoptosis by interfering with Bip-like proteins
EP0921192A1 (en) 1997-12-03 1999-06-09 Leadd B.V. Molecules interacting with apoptin
EP0924296A3 (en) * 1997-12-03 2001-08-01 Leadd B.V. Methods and means for inducing apoptosis by interference in RNA processing
US20030105315A1 (en) 1998-04-09 2003-06-05 Metagen Pharmaceuticals Gmbh Human nucleic acid sequences from ovarian tumor tissue
WO1999057144A2 (en) * 1998-05-05 1999-11-11 Incyte Pharmaceuticals, Inc. Human transcriptional regulator molecules
CA2393859A1 (en) 1999-12-10 2001-06-14 Leadd B.V. Apoptin-associating protein
EP1111045A3 (en) 1999-12-10 2001-09-19 Leadd B.V. Apoptin-associating protein
EP1106691A1 (en) 1999-12-10 2001-06-13 Leadd B.V. Apoptin-associating protein
CA2397571A1 (en) 2000-01-17 2001-07-26 Leadd B.V. Apoptin-associating protein
EP1138765A1 (en) 2000-03-27 2001-10-04 Leadd B.V. Apoptin-associating proteins AAP-5 and AAP-6

Also Published As

Publication number Publication date
WO2001016165A2 (en) 2001-03-08
CA2383784A1 (en) 2001-03-08
NO20021067D0 (no) 2002-03-04
ATE347597T1 (de) 2006-12-15
CN1387569A (zh) 2002-12-25
JP2003510030A (ja) 2003-03-18
US7767790B2 (en) 2010-08-03
CY1106355T1 (el) 2011-10-12
NO20021067L (no) 2002-05-02
EP1083224A2 (en) 2001-03-14
US20080176231A1 (en) 2008-07-24
NZ517740A (en) 2003-09-26
IL148469A (en) 2009-02-11
EA200200321A1 (ru) 2002-08-29
BR0013743A (pt) 2005-01-11
EA005933B1 (ru) 2005-08-25
WO2001016165A3 (en) 2001-09-20
HUP0202688A2 (en) 2002-12-28
EP1083224A3 (en) 2001-04-25
DK1083224T3 (da) 2007-04-10
EP1083224B1 (en) 2006-12-06
DE60032201T2 (de) 2007-09-20
AU781127B2 (en) 2005-05-05
DE60032201D1 (de) 2007-01-18
AU7324200A (en) 2001-03-26
US7317096B1 (en) 2008-01-08
PL354285A1 (pl) 2003-12-29
ES2277815T3 (es) 2007-08-01
PT1083224E (pt) 2007-03-30
PL204275B1 (pl) 2009-12-31
CN100513565C (zh) 2009-07-15

Similar Documents

Publication Publication Date Title
ZA988797B (en) Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds.
ZA988961B (en) Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds.
WO2002057303A3 (en) Protein-protein interactions between shigella flexneri polypeptides and mammalian polypeptides
DK0713529T3 (da) Vækst-/differentieringsfaktor af TGF-beta-familien
DE60215848D1 (de) 1,2,4-thiadiazolverbindungen als melanocortinrezeptor-modulatoren
AU2001260880A1 (en) Pharmaceutical compounds for treating copd
EA200000519A1 (ru) 2-АРИЛБЕНЗО[b]ТИОФЕНЫ, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ СИНДРОМА ЭСТРОГЕННОЙ НЕДОСТАТОЧНОСТИ
AU1559501A (en) Apoptosis inducing proteinaceous substance
EP0990703A4 (en) NEW POLYPEPTIDE, FOR CODING DNA AND THEIR USE
IL148469A0 (en) Apoptin-associating protein
EA200000520A1 (ru) 2-АРИЛ-3-АРОИЛБЕНЗО[b]ТИОФЕНЫ, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ СИНДРОМА ЭСТРОГЕННОЙ НЕДОСТАТОЧНОСТИ
ZA99939B (en) Process for the preparation of 2-aryl-5-(perfluoroalkyl) pyrrole compounds from N-(perfluoroalkylmethyl) arylimidoyl chloride compounds.
WO2001072825A3 (en) Apoptin-associating protein
AU2002257067A1 (en) Tsg101-gag interaction and use thereof
WO2001042461A3 (en) Apoptin-associating protein
EP1111045A3 (en) Apoptin-associating protein
WO2001053351A3 (en) Apoptin bindendes protein
DE60038955D1 (de) AN DER OBERFLÄCHE VON KARZINOMZELLEN LOKALISIERTES COLLIGIN/HsP47
EP1138768A3 (en) Apoptin-associating protein AAP-5
EP1118662A3 (en) Apoptin-associating protein
WO2003060067A3 (en) P85-alpha nucleic acids, polypeptides and related methods
AU2002246455A1 (en) Fusion proteins for specific treatment of cancer and auto-immune diseases
AU2003249999A1 (en) 1,4,7,10-tetraazacyclododecanes as modulators of the guanine-binding protein for treating tumours
AU2002311573A1 (en) Polymorphism in the eosinophil cationic protein (ecp) used in the treatment of e.g. cancer
WO2001020335A3 (en) Methods for modulating cell proliferation

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed